SPRY
Price
$14.08
Change
-$0.00 (-0.00%)
Updated
Nov 13 closing price
126 days until earnings call
TARS
Price
$46.51
Change
-$0.00 (-0.00%)
Updated
Nov 13 closing price
123 days until earnings call
Ad is loading...

SPRY vs TARS

Header iconSPRY vs TARS Comparison
Open Charts SPRY vs TARSBanner chart's image
ARS Pharmaceuticals
Price$14.08
Change-$0.00 (-0.00%)
Volume$3.2M
CapitalizationN/A
Tarsus Pharmaceuticals
Price$46.51
Change-$0.00 (-0.00%)
Volume$857.86K
CapitalizationN/A
SPRY vs TARS Comparison Chart
Loading...
SPRY
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
TARS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
SPRY vs. TARS commentary
Nov 15, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SPRY is a Hold and TARS is a Hold.

COMPARISON
Comparison
Nov 15, 2024
Stock price -- (SPRY: $14.08 vs. TARS: $46.50)
Brand notoriety: SPRY and TARS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: SPRY: 298% vs. TARS: 106%
Market capitalization -- SPRY: $1.36B vs. TARS: $1.77B
SPRY [@Biotechnology] is valued at $1.36B. TARS’s [@Biotechnology] market capitalization is $1.77B. The market cap for tickers in the [@Biotechnology] industry ranges from $473.6B to $0. The average market capitalization across the [@Biotechnology] industry is $2.76B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

SPRY’s FA Score shows that 0 FA rating(s) are green whileTARS’s FA Score has 0 green FA rating(s).

  • SPRY’s FA Score: 0 green, 5 red.
  • TARS’s FA Score: 0 green, 5 red.
According to our system of comparison, TARS is a better buy in the long-term than SPRY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

SPRY’s TA Score shows that 2 TA indicator(s) are bullish while TARS’s TA Score has 4 bullish TA indicator(s).

  • SPRY’s TA Score: 2 bullish, 7 bearish.
  • TARS’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, TARS is a better buy in the short-term than SPRY.

Price Growth

SPRY (@Biotechnology) experienced а -10.43% price change this week, while TARS (@Biotechnology) price change was -0.64% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.83%. For the same industry, the average monthly price growth was +3.51%, and the average quarterly price growth was +6.16%.

Reported Earning Dates

SPRY is expected to report earnings on Mar 20, 2025.

TARS is expected to report earnings on Mar 17, 2025.

Industries' Descriptions

@Biotechnology (-1.83% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
TARS($1.77B) has a higher market cap than SPRY($1.37B). SPRY YTD gains are higher at: 156.934 vs. TARS (129.630). SPRY has higher annual earnings (EBITDA): -56.74M vs. TARS (-144.23M). TARS has more cash in the bank: 324M vs. SPRY (219M). SPRY has less debt than TARS: SPRY (160K) vs TARS (72.2M). TARS has higher revenues than SPRY: TARS (83.4M) vs SPRY (500K).
SPRYTARSSPRY / TARS
Capitalization1.37B1.77B77%
EBITDA-56.74M-144.23M39%
Gain YTD156.934129.630121%
P/E RatioN/AN/A-
Revenue500K83.4M1%
Total Cash219M324M68%
Total Debt160K72.2M0%
TECHNICAL ANALYSIS
Technical Analysis
SPRYTARS
RSI
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
88%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
79%
N/A
MACD
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 4 days ago
86%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 4 days ago
85%
Bullish Trend 16 days ago
83%
Declines
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
83%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
85%
View a ticker or compare two or three
Ad is loading...
SPRY
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
TARS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GGYPX17.45N/A
N/A
Goldman Sachs Focused Value P
CVLCX11.11-0.01
-0.09%
Calamos Global Opportunities C
VCRAX13.53-0.06
-0.44%
NYLI CBRE Global Infrastructure Class A
SGTTX84.52-0.57
-0.67%
Columbia Seligman Global Tech Inst2
MGRTX43.60-0.41
-0.93%
MFS International Growth R3

SPRY and

Correlation & Price change

A.I.dvisor indicates that over the last year, SPRY has been loosely correlated with LPCN. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if SPRY jumps, then LPCN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SPRY
1D Price
Change %
SPRY100%
-15.23%
LPCN - SPRY
63%
Loosely correlated
+1.57%
INZY - SPRY
44%
Loosely correlated
-5.59%
ACLX - SPRY
42%
Loosely correlated
-0.34%
VIR - SPRY
39%
Loosely correlated
-2.92%
OABI - SPRY
38%
Loosely correlated
-9.35%
More

TARS and

Correlation & Price change

A.I.dvisor indicates that over the last year, TARS has been loosely correlated with DNLI. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if TARS jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TARS
1D Price
Change %
TARS100%
-2.25%
DNLI - TARS
35%
Loosely correlated
-0.84%
BEAM - TARS
35%
Loosely correlated
-1.57%
SPRY - TARS
34%
Loosely correlated
-15.23%
ADMA - TARS
33%
Loosely correlated
-1.40%
MDGL - TARS
33%
Loosely correlated
-7.05%
More